MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report 1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
TESTING,89027	C7028846−001944	31	F	R1057715
Ordering Phys TEST,DOCTOR				**DOB** 08/01/1981
Client Order # R1057715	**Account Information**			**Report Notes**
Collected 07/01/2013 08:45	C7028846-DLMP Rochester 3050 Superior Drive Rochester, MN 55901			
Printed 07/16/2013 13:45				

Test	Flag	Results	Unit	Reference Value	Perform Site*

Ki-67(MIB-1), Breast IHC, Automated
RECEIVED: 07/01/2013 09:16 **REPORTED:** 07/01/2013 10:19

Accession Number HR13-255 MCR

Referring Pathologist/Physician MCR
Doctor Test Jr., M.D.

Ref Path/Phys Address MCR
Methodist Hospital
200 1st Street SW
Rochester, MN 55905
507-266-0740

Material: MCR
right breast - 1 block (S13-4348)

Tissue: MCR
A:Breast, right sided, mass at 10 o'clock, ultrasound guided needle core biopsy

Interpretation: MCR
Ki-67 (MIB-1), Breast IHC, Automated:
Source: Breast, right sided, biopsy, block S13-4348
Proliferation index Ki-67 (MIB-1) = 37.6%.
Ki-67 (MIB-1) proliferation data must be interpreted within the clinical context for which the test was ordered. Recent studies have suggested that Ki-67 (MIB-1) analysis of paraffin-embedded breast cancer tissue specimens may provide useful prognostic information.
1. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005 Oct 1;23(28):7212-7220
2. de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007 May 21;96(10):1504-1513 Epub 2007 Apr 24
Method: Immunohistochemical staining of the Ki-67 antigen in formalin-fixed paraffin-embedded tissue sections has been validated by our laboratory, using the MIB-1 clone and a proprietary detection system. All controls show appropriate reactivity. Ki-67 (MIB-1)-stained-slides are scanned using the Aperio ScanScope instrument, which captures digital images of the patient slide. A technologist views the digitized image on a computer monitor and using a tracing tool available in ImageScope (Aperio Technologies Inc), traces around areas of invasive or metastatic cancer capturing no less than 75% of the total cancer within the image. The traced areas are then analyzed using an image analysis algorithm that renders the percentage of positive-staining tumor nuclei. The slides and test results are then reviewed by a pathologist who provides a final interpretation.
Laboratory Developed Test

Performing Site Legend on Last Page of Report

* Report times for Mayo performed tests are CST/CDT

MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report 1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
TESTING,89027	C7028846−001944	31	F	R1057715
Ordering Phys TEST,DOCTOR				**DOB** 08/01/1981
Client Order # R1057715	**Account Information**			**Report Notes**
Collected 07/01/2013 08:45	C7028846-DLMP Rochester 3050 Superior Drive Rochester, MN 55901			
Printed 07/16/2013 13:45				

Test	Flag	Results	Unit	Reference Value	Perform Site*
SP Signing Pathologist:		See Below			MCR

Result:7/1/2013 10:19 Interpreted by: Pathologist X. Test, M.D.
Report electronically signed by Angie S. Beckel
Transcribed by: asa05 7/1/2013 09:59:42

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.

* Report times for Mayo performed tests are CST/CDT